Antiproliferative Activity of Violaxanthin Isolated from Bioguided Fractionation of Dunaliella tertiolecta Extracts

• Main Authors: Laurent Picot, Thierry Patrice, Jean-Paul Cadoret, Jean-Marie Piot, Mathieu Lafferriere, Isabelle Lanneluc, Valerie Thiery, Raymond Kaas, Jean-Baptiste Berard, Benoit Serive, Lucie Aumailley, Said Ihammouine, Amandine Chepied, Virginie Pasquet, Perrine Morisset
• Format: Article
• Language: English
• Published: MDPI AG 2011-05-01
• Series: Marine Drugs
• Subjects: pigments; microalgae; Dunaliella; violaxanthin; carotenoid; cancer; apoptosis
• Online Access: http://www.mdpi.com/1660-3397/9/5/819/

Dunaliella tertiolecta (DT) was chemically investigated to isolate molecules inhibiting cancer cell proliferation and inducing apoptosis in vitro. The potency to inhibit cell growth was used for the bio-guided fractionation and isolation of active compounds using chromatographic techniques. The DT dichloromethane extract exhibited a strong anti-proliferative activity on MCF-7 and LNCaP cells, and was further fractionated and sub-fractionated by RP-HPLC. High resolution mass spectrometry and spectrophotometric analysis unequivocally identified violaxanthin as the most antiproliferative molecule present in DT DCM extract. Violaxanthin purified from DT induced MCF-7 dose-dependent growth inhibition in continuous and discontinuous treatments, at concentrations as low as 0.1 µg·mL−1 (0.17 µM). Phosphatidylserine exposure, typical of early apoptosis, was observed after 48 h treatment at 8 µg·mL−1 (13.3 µM) but no DNA fragmentation, characteristic of late apoptosis steps, could be detected even after 72 h treatment at 40 µg·mL−1 (66.7 µM). Taken together, our results demonstrate the strong antiproliferative activity of violaxanthin on one human mammary cancer cell line, and suggest that studying the pharmacology of violaxanthin and pharmacomodulated derivatives on cancer cells may allow potent antiproliferative drugs to be obtained.